본문내용 바로가기

Services
End-to-End CDMO Services based on technological Expertise

GMP Manufacturing
KOLON Biotech has excellent capability in dealing with various types of ATMP products like cell and gene therapy and exosome therapy. we can satisfy any specific needs of our customers at every stage of biopharmaceutical development.
We can address any manufacturing hurdles in every step of product life cycle.
We’re able to conduct a new process adaptation by Tech Transfer and Scale out or Scale up, Future Area for Capacity buildup.

Therapy Type

  • 1
    Somatic cell
  • 2
    Stem cell(MSC, iPSC, etc.)
  • 3
    Exosome
service service

Track Record

KOLON Biotech has accumulated a strong track record providing CDMO services to various customers for a wide range of biopharmaceutical products.
example
Selective examples
No. Product
1 Cell Therapy
2 Gene-modified Cell Therapy
3 Gene-modified Stem Cell Therapy
4 Exosome Therapy
5 Stem Cell Therapy
No. Product Service Phase
Process
Development
GMP
Manufacturing
Storage
1 Cell Therapy
check
check
check
Clinical / Commercial
2 Gene-modified Cell Therapy
check
check
check
Clinical / Commercial
3 Gene-modified Stem Cell Therapy
check
check
Clinical
4 Exosome Therapy
check
check
check
Clinical
5 Stem Cell Therapy
check
check
check
Clinical

Scale-up Technology

2D Cell Production Platform (Developing)
manufacturing adherent cells in large scale with minimum cost and failure risk
  • service process
    T-flask
  • service process
    Medium Scale
    multi-layer flask
  • service process
    Large Scale Culture
    vessel w/ automated
    device
  • service process
    Continuous
    Centrifuge
  • service process
    Bag-type
    filtration
  • service process
    Vial filling
  • service process
    T-flask
  • service process
    Medium Scalemulti-layer flask
  • service process
    Large Scale Culture vessel w/ automated device
  • service process
    ContinuousCentrifuge
  • service process
    Bag-typefiltration
  • service process
    Vial filling
  • Closed process addresses the risk of contamination during the open process
  • Semi-automated manipulation ensures high batch-to-batch consistency & reduced processing time
3D Cell Production Platform (Developing)
Conversion of adherent cell culture method from 2D to 3D using microcarrier & bioreactor
TOP